RENO, Nev.--(BUSINESS WIRE)--Today, Dr. Louis Keith, Vice President and Medical Director of Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN), commented on an article published online by the New England Journal of Medicine yesterday. “This publication is a top medical journal and the reported data is excellent. The study, conducted at 25 U.S. test sites, was paid for by the National Institutes of Health. As a result, the American Cancer Society suggests that high-risk women and those with diagnosed breast cancer in one breast get an MRI. This procedure can cost $2,000 or more which is not reimbursable by Medicare or private insurance carriers.”
